Sonia Moretti

ORCID: 0000-0003-4812-1496
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Viral-associated cancers and disorders
  • HIV Research and Treatment
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Thyroid Cancer Diagnosis and Treatment
  • HIV/AIDS drug development and treatment
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Cancer-related Molecular Pathways
  • S100 Proteins and Annexins
  • Cytomegalovirus and herpesvirus research
  • Cancer, Hypoxia, and Metabolism
  • Advanced Proteomics Techniques and Applications
  • Virology and Viral Diseases
  • Anesthesia and Neurotoxicity Research
  • Ferroptosis and cancer prognosis
  • HIV-related health complications and treatments
  • Galectins and Cancer Biology
  • Cancer, Stress, Anesthesia, and Immune Response
  • HIV/AIDS Research and Interventions
  • Sphingolipid Metabolism and Signaling
  • Genetic factors in colorectal cancer
  • Pancreatic function and diabetes
  • vaccines and immunoinformatics approaches
  • Protein Tyrosine Phosphatases

University of Perugia
2014-2025

University of Rome Tor Vergata
2025

Istituto Superiore di Sanità
2014-2024

European Institute of Oncology
2012

Sapienza University of Rome
1991-2009

University of Zurich
2009

Policlinico Umberto I
2004-2008

University of L'Aquila
1992-2006

IRCCS San Camillo Hospital
2001

Committee on Publication Ethics
2001

Abstract Context: BRAF mutations are common in papillary thyroid carcinomas (PTCs). By affecting the expression of genes critically related to development and differentiation cancer, they may influence prognosis these tumors. Objective: Our objective was characterize thyroid-specific associated with mutation PTCs. Design/Setting Patients: We examined key markers thyrocyte 56 PTCs (BRAF-mut) 37 wild-type (BRAF-wt). Eight samples normal tissue were analyzed as controls. Quantitative PCR used...

10.1210/jc.2006-2707 article EN The Journal of Clinical Endocrinology & Metabolism 2007-05-09

Noonan, LEOPARD, and cardiofaciocutaneous syndromes (NS, LS, CFCS) are developmental disorders with overlapping features including distinctive facial dysmorphia, reduced growth, cardiac defects, skeletal ectodermal anomalies, variable cognitive deficits. Dysregulated RAS-mitogen-activated protein kinase (MAPK) signal traffic has been established to represent the molecular pathogenic cause underlying these conditions. To investigate phenotypic spectrum diversity of germline mutations...

10.1002/humu.20955 article EN Human Mutation 2009-02-10

Activating mutations of BRAF have been identified in a variety human cancers, most notably melanomas and papillary thyroid carcinomas (PTCs). The aim the present study was to disclose role carcinoma development. Seventy-two tumors, including 60 PTCs, six follicular adenomas, five carcinomas, one anaplastic carcinoma, were studied. mutation screening focused on exon 15 11 gene by single-stranded conformational polymorphism sequence analysis. Search RET/PTC expression conducted with RT-PCR...

10.1210/jc.2003-031425 article EN The Journal of Clinical Endocrinology & Metabolism 2004-05-01

Recently, a somatic point mutation of the B-RAF gene (V600E) has been identified as most common genetic event in papillary thyroid carcinoma (PTC), with prevalence variable among different series. Since discordant data on clinico-pathologic features mutated PTC are present literature, aim co-operative study was to establish this alteration and perform genotype–phenotype correlation large cohort patients PTC. To purpose, series 260 sporadic PTCs histological variants were included study. The...

10.1677/erc.1.01086 article EN Endocrine Related Cancer 2006-05-25

Abstract Vaccination of cynomolgus monkeys with the biologically active HIV-1 Tat protein induces specific Th1 responses, including CTLs. Similar responses are also induced by vaccination tat DNA, but not inactivated or peptides. This suggested that native may act differently on APC as compared peptide Ag. In this study, we show is very efficiently taken up monocyte-derived dendritic cells (MDDC) in a time (within minutes)- and dose-dependent (starting from 0.1 ng/ml) fashion, whereas uptake...

10.4049/jimmunol.168.1.197 article EN The Journal of Immunology 2002-01-01

Evidence for an increased prevalence of BRAFV600E mutations has been documented in recent decades. The aim this study was to evaluate the both RET/PTC rearrangements and Italian cohort papillary thyroid carcinoma (PTC) patients followed at Endocrine Units Pisa, Milano, Perugia from 1996–2010. In total, 401 PTC were examined grouped according time surgery: group 1, 1996–2000; 2, 2001–2005; 3, 2006–2010. Patients analyzed clinical, pathological, molecular features. parallel, characteristics...

10.1210/jc.2012-1269 article EN The Journal of Clinical Endocrinology & Metabolism 2012-06-29

Indoleamine 2,3-dioxygenase 1 (IDO1) is a single chain oxidoreductase that catalyzes tryptophan degradation to kynurenine. In cancer, it appears exert an immunosuppressive function as part of acquired mechanism immune escape mediated by the inhibition lymphocyte proliferation and survival induction FoxP3+ T regulatory cells.The objective study was evaluate IDO1 expression in thyroid carcinoma demonstrate its context tumors.IDO1 evaluated quantitative PCR 105 papillary carcinomas (PTCs), 11...

10.1210/jc.2013-3351 article EN The Journal of Clinical Endocrinology & Metabolism 2014-02-11

The understanding of the mechanisms underlying thyroid cancer immune escape can lead to identification new molecular targets and/or efficacy biomarkers. For this purpose, we performed expression profiling in cancers obtain a comprehensive view on activated during progression. study was conducted retrospectively 25 papillary carcinomas (PTCs), 14 poorly differentiated (PDTC), 13 anaplastic (ATCs), and 7 normal (NT) tissue samples. Gene obtained RNA samples using Nanostring platform its...

10.1210/jc.2018-01167 article EN The Journal of Clinical Endocrinology & Metabolism 2019-03-18

Methylglyoxal (MG) is a potent inducer of advanced glycation end products (AGEs). MG, long considered highly cytotoxic molecule with potential anticancer value, now being re-evaluated to protumorigenic agent in some malignancies. Anaplastic thyroid cancer (ATC) an extremely aggressive and lethal for which conventional therapies have proved ineffective. Successful therapeutic intervention ATC undermined by our poor understanding its molecular etiology. In the attempt understand role MG...

10.3390/cells8060547 article EN cc-by Cells 2019-06-06

Abstract Background The programmed cell death-1 (PD-1) receptor and its ligands PD-L1 PD-L2 are immune checkpoints that suppress anti-cancer immunity. Typically, cancer cells express the PD-Ls bind PD-1 on cells, inhibiting their activity. Recently, expression has also been found in cells. Here, we analysed functions of thyroid (TC). Methods was evaluated by immunohistochemistry human TC samples RT-PCR, western blot FACS lines. Proliferation migration culture were assessed BrdU incorporation...

10.1186/s13046-020-01818-1 article EN cc-by Journal of Experimental & Clinical Cancer Research 2021-01-07

Objective: A severe dose-limiting axonal peripheral neuropathy may develop in subjects on treatment with the nucleoside analogues didanosine (ddI), zalcitabine (ddC), and stavudine (d4T). The impairment of mitrochondrial DNA synthesis is crucial to pathogenesis this disorder although other mechanisms have not been ruled out. depletion acetyl-carnitine, which regulates metabolism function nerves, could contribute neurotoxicity these compounds. Design: Non-randomized, cross-sectional study...

10.1097/00002030-199702000-00008 article EN AIDS 1997-02-01

In 15 elderly individuals lyophilized Bifidobacterium bifidum (BB) and Lactobacillus acidophilus (LA) (Infloran®) were administered in capsules (two 4 times per day) for 28 days, while 10 controls placebo given the same posology an equal period of time. The effects this treatment on immune system both at periphery or intestinal level investigated. Results show that BB LA significantly reduced colonic inflammatory infiltration, without altering T, B Leu7+ cell percentage. At time, a...

10.3109/08923979209009228 article EN Immunopharmacology and Immunotoxicology 1992-01-01

Objective Reduced levels of serum carnitines (3-hydroxy-4-N-trimethyl-ammonio-butanoate) are found in most patients treated with zidovudine. However, since do not strictly reflect cellular concentrations we examined whether a carnitine depletion could be peripheral blood mononuclear cells (PBMC) from AIDS normal levels. In addition, explored it was posssible to relate the host's immunoreactivity content PBMC and can corrected by oral supplementation L-carnitine. Design Immunopharmacologic...

10.1097/00002030-199405000-00012 article EN AIDS 1994-05-01

RET/PTC rearrangements represent key genetic events involved in papillary thyroid carcinoma (PTC) initiation. The aim of the present study was to identify early changes gene expression induced by cells. For this purpose, microarray analysis conducted on PCCL3 cells conditionally expressing RET/PTC3 oncogene. Gene profiling 48 h after activation identified a statistically significant modification 270 genes. Quantitative PCR confirmation 20 these demonstrated 90% accuracy microarray....

10.1677/erc.1.00947 article EN Endocrine Related Cancer 2005-06-01

Summary Objectives The genes RET and RAS , more recently BRAF have been shown to be frequently mutated in human papillary thyroid carcinomas (PTC). aim of this study was genotype for these mutations a cohort tumours collected at our institutions. Design patients Thyroid removed from 51 subjects were analysed, including 43 PTC 8 non‐PTC [3 follicular adenomas (FA), 4 (FTC) 1 anaplastic carcinoma (AC)]. Measurements /PTC1 /PTC3 expression evaluated by reverse transcriptase‐polymerase chain...

10.1111/j.1365-2265.2005.02401.x article EN Clinical Endocrinology 2005-11-18

AbstractSeveral reports indicate that systemic carnitine deficiency could occur in acquired immunodeficiency disease syndrome (AIDS), and primary secondary leads to critical metabolic dysfunctions.L-carnitine supplementation peripheral blood mononuclear cells (PBMCs) of AIDS patients resulted significant enhancement the phytohemagglutinin (PHA)-driven proliferative response. High dose L-carnitine administration (6 gr per day for two weeks) treated with zidovudine also led increased PBMCs...

10.3109/08923979309066930 article EN Immunopharmacology and Immunotoxicology 1993-01-01

Portable blood glucose meters (PBGMs) are useful in the management of diabetes mellitus cats. In present study we compared performance two PBGMs: AlphaTRAK (Abbott Animal Health, Maidenhead, England) specifically developed for dogs and cats, Ascensia ELITE (Bayer HealthCare, Zurich, Switzerland) humans. Quality parameters, including precision accuracy, were better meter to ELITE. While results did not differ from reference method, significantly (P<0.001) lower. The superior supports its use...

10.1024/0036-7281.151.9.448 article EN Schweizer Archiv für Tierheilkunde 2009-09-01

Tat is an early regulatory protein that plays a major role in human HIV-1 replication and AIDS pathogenesis, therefore, it represents key target for the host immune response. In natural infection, however, Abs against are produced only by small fraction (approximately 20%) of asymptomatic individuals rarely seen progressors, suggesting may possess properties diverting adaptive immunity from generating humoral responses. Here we show Th1-type T cell response predominant over Th2-type B...

10.4049/jimmunol.0711406 article EN The Journal of Immunology 2009-02-20

Use of Env in HIV vaccine development has been disappointing. Here we show that, the presence a biologically active Tat subunit vaccine, trimeric protein prevents monkeys virus spread from portal entry to regional lymph nodes. This appears be due specific interactions between and spikes that form novel complex favoring R5 or X4 productive infection dendritic cells (DCs) via an integrin-mediated pathway. These effects do not require Tat-transactivation activity are blocked by anti-integrin...

10.1371/journal.pone.0048781 article EN cc-by PLoS ONE 2012-11-13

The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and safety of biologically active HIV-1 Tat protein administered 7.5 or 30 μg, given 3 5 times monthly, exploring immunological virological disease biomarkers. study duration 48 weeks, however, vaccinees were followed until last enrolled subject reached weeks. Reported are final data up to 144 weeks follow-up. ISS T-002 conducted in 11...

10.1186/s12977-015-0151-y article EN cc-by Retrovirology 2015-04-24
Coming Soon ...